GlaxoSmithKline says demand for its Meningitis B Bexsero vaccine is too high for the drugmaker to keep up with orders.
The shortage will affect private clinics in the UK.
According to GSK, "Although vaccination through the NHS childhood program has been prioritized and is unaffected, we have unfortunately had to ask private clinics temporarily to not start new courses of vaccination."
In January 2013, Bexsero was approved by the European Commission for use in individuals from 2 months of age and older, making it the first broad coverage vaccine to receive a regulatory approval to help protect against meningitis B.
According to the Telegraph, Britain is the first country in the world to launch a nationwide meningitis B vaccination program.
Read the Telegraph article